CORRECTING and REPLACING Connected Objects: a Global Ambition at Total
Please replace the release dated July 10, 2018 with the following corrected version due to multiple revisions.
The corrected release reads:
CONNECTED OBJECTS: A GLOBAL AMBITION AT TOTAL
Total has joined forces with Sigfox, the world’s leading IoT connectivity service, to deploy a solution designed to optimise rolling stock and help manage trailer fleets.
What’s the solution?
Created by transporters, for transporters, Where’s my Trailer? is an innovative new way to improve how trailer fleets are used and kept secure.
The solution works by installing a box on the trailer, to identify any equipment that is underused or has been lost or stolen.
The solution was developed by Total Marketing France through its subsidiary Stela and has been in test phase for a year with the company’s transporter customers.
“Sigfox technology, together with our proximity to Freight and Logistics, has given us the opportunity to offer a reliable and efficient way of geolocalising rolling stock throughout Europe,” explains Benoît Luc, Director of Total’s European Marketing & Services Department.
“We are delighted with how the Total project has developed,” adds Patrick Cason, Managing Director of Sigfox France. “The significant size of the Total group has in no way hindered our progress, in fact quite the opposite. We have seen how its full force can really benefit innovation. The group knows how to listen to its customers, how to think about their experience as users, and how to commit to providing innovative services. Our teams worked together very easily because Total both responds and makes decisions promptly.”
How it works
The boxes are self-powered and very easy to install on the trailer. They communicate using Sigfox technology, which is able to provide a low bandwidth connection network at a very low cost.
Where’s my Trailer? localises any stationery trailers and allows users to set up notifications. Messages are displayed on the secure customer portal, which can be accessed from the websites stela.fr and as24.com,and are compatible with all digital devices.
Maps and dashboards provide information on:
- Trailers and a track record of inactive periods
- Tractor-trailer pairing – drop-and-hook detection
- Maintenance – vehicle safety inspection, repairs
- Unauthorised movement during time periods can be configured by the customer
How to access the service
Where’s My Trailer? is easy to deploy and use, and is very competitively priced on the transport market.
This solution marks the end of high costs and complex systems: benefiting from Sigfox’s services and international network, this disruptive solution both significantly reduces costs and simplifies the system’s implementation, unlike current solutions that are complex to deploy.
It will be available from July 9, 2018, first in France and then in Europe, through Stela and AS24. There will also be a hotline open 5 days a week, to help customers install their boxes, use the secure portal, and configure their options. Where’s my Trailer? is free to download – the only requirement is to purchase a subscription.
The solution is scalable and will soon include new features.
This press release is for informational purposes only and shall have no legal consequences. The entities in which TOTAL SA directly or indirectly owns a stake are separate and autonomous. TOTAL SA shall not be held liable for the actions or omissions of the aforementioned companies. The terms “TOTAL”, “TOTAL Group” and “Group” as presented in this document are generic and used for convenience only. Similarly, the terms “we”, “us” and “our” may also be used to refer to subsidiaries or employees of those subsidiaries.
This document may contain forward-looking information and statements that are based on economic data and assumptions made based on a particular economic, competitive and regulatory context. They may prove inaccurate in the future and are dependent on risk factors. Neither TOTAL SA nor any of its affiliates make any commitment or take on any responsibility in relation to investors or any other party to update or revise any or all statements, forward-looking information, trends or objectives contained in this document, especially as a result of new information or future events.
Eleanor Burgess +44 (0)7773931979
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 09:30 | Pressemelding
Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00 | Pressemelding
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac
Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05 | Pressemelding
Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations
Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40 | Pressemelding
Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37 | Pressemelding
Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He
Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43 | Pressemelding
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.